Dihydroberberine (commonly sold under the branded form GlucoVantage) is a reduced form of Berberine that converts to Berberine in the intestinal lining. Because of this conversion mechanism, it is absorbed considerably more efficiently than standard Berberine HCL, allowing for a fraction of the dose while targeting the same AMPK-activation pathway.
Clinical Summary
Clinical and pharmacokinetic data indicate Dihydroberberine is up to roughly 5 times more bioavailable than standard Berberine HCL, allowing lower doses while reducing the gastrointestinal burden associated with high-dose Berberine.
Dosage Guidelines
100mg to 200mg daily, generally divided into 1-2 doses with meals.
Safety & Side Effects
Better tolerated than standard Berberine HCL, with a lower incidence of gastrointestinal discomfort due to the reduced dose required.
Known Interactions
Shares the same theoretical interaction profile as Berberine, including CYP3A4 enzyme inhibition; use caution with blood thinners, statins, and hypoglycemic medications.
Medical Disclaimer
The information provided in this clinical review is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
*These statements have not been evaluated by the Food and Drug Administration (FDA). This product or ingredient is not intended to diagnose, treat, cure, or prevent any disease.
Always consult your physician or other qualified health provider with any questions you may have regarding a medical condition, or before beginning any new diet, fitness, supplement, or treatment regimen, especially if you have pre-existing medical conditions or are taking prescribed medications.
